Brought to you by 
Allergan builds NASH business through $50mm Akarna buy
27 May 2021
Executive Summary
Continuing with its September buying spree, Allergan PLC announced that it is paying $50mm in cash to acquire Akarna Therapeutics Ltd., a two-year-old firm developing small-molecule therapies for fibrotic and inflammatory diseases.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Allergan builds NASH business through $50mm Akarna buy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice